LSD Derivatives: Conceivable Risks - A Sober Look at Potential Side Effects

LSD derivatives are often discussed as legal alternatives to classic hallucinogens. But beyond chemistry and the legal situation, a crucial question arises: what dangers and risks do these substances actually pose to consumers?

While physical side effects are often considered comparatively minor, the real potential danger lies primarily in their influence on the psyche. The intense alteration of sensory perception, experience, thought, and emotion can be enriching, but it can also lead to challenging states.

At the same time, LSD research shows remarkable results, indicating that the use of a psychedelic in a controlled therapeutic setting could help people with mental illnesses.

This article takes a sober, differentiated look at the possible side effects of LSD derivatives. It is not about dramatization, but about an objective classification of physical, psychological, and long-term risks, as well as interactions when used concurrently with other substances.

Note: 1Fe-LSD and 1BP-LSD are not intended for human consumption. All described content is based on scientific sources or subjective experience reports and is not to be understood as instructions or recommendations.

Since LSD derivatives such as 1Fe-LSD and 1BP-LSD are most likely metabolized in the body into lysergic acid diethylamide (LSD-25), developed by Albert Hofmann, their risks and side effects are identical.

Compared to many other psychoactive substances, LSD is considered remarkably safe physiologically. There are no documented deaths directly attributable to a toxic overdose of LSD-25, and the lethal dose is estimated to be a thousand times the normal recreational dose. The direct physical effects are mostly harmless and subside quickly. They result from the activation of the sympathetic nervous system, which controls our "fight or flight" responses.

The most common physical side effects include:

• Dilated pupils (Mydriasis): One of the most reliable external signs of consumption.

• Increased blood pressure and heart rate: Usually moderate increases that are harmless for healthy individuals, but can pose a risk for people with pre-existing cardiovascular conditions.

• Increased body temperature (Hyperthermia): Usually only a slight increase.

• Other effects: Sweating or chills, loss of appetite, dry mouth, nausea, insomnia, and occasionally muscle tremors or weakness.

These symptoms are usually not dangerous and subside as the psychological effects wear off. The actual risks of LSD consumption are almost exclusively psychological.

The most significant acute risk of consuming LSD alternatives is the possibility of a psychologically extremely stressful experience, colloquially known as a "bad trip."

This is not a toxic reaction, but a state of intense anxiety, panic, confusion, and paranoia, triggered by the drug-induced alteration of consciousness.

A bad trip is not an experience detached from reality, but rather an experience triggered by an unsuitable or perceived unsafe environment or a mind unprepared for the experience. This is where the concept of "set and setting" becomes relevant: both the environment chosen for the trip and one's own state of mind should be ready and safe for the entire duration of the psychedelic journey. Therefore, it may be advisable to have the experience take place in a professionally supervised environment.

During a bad trip, the user, according to experience reports, may feel like they are losing their mind, irrevocably losing control of themselves, or even dying. Distorted perception can take on threatening forms, and harmless stimuli can be interpreted as terrifying. Such experiences can be deeply traumatizing. A bad trip under psychotropic substances is mainly caused by the "set" (internal state) and "setting" (external environment). Psychological instability, stress, anxieties, or negative expectations ("set") increase the risk. An unsafe, noisy, or unfamiliar environment ("setting") also has a negative impact. A high dose of the substance is another significant risk factor, especially for inexperienced consumers.

The greatest danger arising from a bad trip is the resulting behavior. Judgment is severely impaired under the influence of LSD. In a state of panic or paranoia, possibly intensified by pseudo-hallucinations, a person can make irrational and dangerous decisions that can lead to accidents, self-harm, or in extremely rare cases, aggressive behavior.

Most incidents related to LSD consumption are not due to the substance itself, but to accident-related behavior. This emphasizes that safety in LSD consumption depends less on toxicology and more on psychological preparation and environmental control.

Although most LSD experiences end without lasting negative consequences, there are two rare but serious long-term risks that must be considered.

For individuals with a predisposition to mental illness, LSD use poses a significant risk.

The course of an intense psychedelic experience can be a considerable strain. In vulnerable individuals, it can trigger a latent mental disorder (e.g., psychosis, schizophrenia) or worsen an existing condition.

People with a personal or family history of psychotic disorders are therefore strongly advised against taking psychedelics.

This is the greatest psychological risk and the main reason why careful psychiatric screening of participants is essential in clinical studies.

Compared to many other drugs, the addiction potential of LSD-25 is very low from a scientific perspective.

• Tolerance: The body develops tolerance to the effects of LSD extremely quickly. After only a few consecutive days of use, the effect is greatly diminished or completely absent. This is due to a rapid downregulation of 5-HT2A receptors in the brain as a protective mechanism against overstimulation. This rapid development of tolerance makes daily, compulsive use, as observed with drugs like cocaine or heroin, practically impossible and unattractive. Tolerance also subsides just as quickly after a few days of abstinence.

• Dependence: LSD is not considered physically addictive. There is no classical withdrawal syndrome with physical symptoms when use is discontinued. While psychological dependence, a strong craving for the substance's effects, is theoretically possible, it is rarely observed in practice. The intensity and long duration of the experience tend to encourage most users to take longer breaks between doses. The risk of addiction is generally considered low, especially compared to addictive substances like alcohol or tobacco or other common drugs.

Combining LSD-25 or LSD derivatives with other drugs or medications is unpredictable and potentially dangerous.

• Alcohol: Combining with alcohol can lead to nausea, vomiting, and disorientation. Alcohol can further impair judgment and increase the risk of impulsive actions.

• Stimulants (e.g., amphetamines, cocaine): This combination can dangerously increase blood pressure and heart rate and heighten the risk of anxiety and paranoia.

• Cannabis can unpredictably intensify the psychedelic effects, particularly visual effects. This can quickly turn an otherwise manageable experience into an overwhelming and anxiety-ridden one.

• Other psychedelics (e.g., psilocybin): LSD and LSD analogues should not be taken with other hallucinogens, even if this is common practice in party settings. These psychedelics can amplify each other in unpredictable ways and increase the risk of unpleasant LSD trips.

• Medications: Special caution is required when combining with medications that affect the central nervous system. Antidepressants, particularly SSRIs, can influence the effects of LSD, while others, such as lithium or MAOIs, can lead to dangerous interactions, including the potentially life-threatening serotonin syndrome.

A fundamental rule for risk minimization is therefore never to consume psychedelics in combination with other substances or medications without thoroughly informing yourself about the properties of the active substance and possible interactions.

To make the substance marketable without legal penalties based on the legal-by-design principle, legal LSD derivatives have side chains attached to the indole ring. These side chains also result in a higher mass for the newly created LSD derivatives compared to classic LSD-25. This impacts the dosage.

The LSD-25 molecule has a molar mass of 323.4 g/mol.

A look at the molecular properties illustrates the differences between the individual derivatives: The 1BP-LSD molecule, due to its side group with a boron-containing heterocycle, has a comparatively high molar mass of 609.6 g/mol, making it significantly heavier than classic LSD-25. Theoretical calculations suggest that approximately 188 µg of 1BP-LSD would be required to achieve the intensity of effect of a 100-µg dose of LSD-25. For researchers, this means that the dose would have to be increased by about 1.9 times to achieve an approximately comparable pharmacological effect.

1Fe-LSD has a lower molar mass than 1BP-LSD at 535.5 g/mol, but due to the attached ferrocene side chain, it is also significantly heavier than LSD-25. To achieve the effect of 100 µg of LSD-25, approximately 165 µg of 1Fe-LSD would theoretically be necessary. Accordingly, the required dose would be about 1.65 times higher to achieve a comparable potency to classic LSD.

Interested parties should consider this information to avoid unintentional, incorrect dosages when researching these substances.

Beyond health aspects, the legal classification of LSD derivatives is a central issue. Many of these substances temporarily exist in a legal loophole, as they are structurally modified in such a way that they do not immediately fall under existing prohibitions.

This approach leads to an ongoing cat-and-mouse game between manufacturers and legislators, particularly in the context of the New Psychoactive Substances Act. What is not explicitly covered today could be prohibited tomorrow by an amendment.

For interested parties, this creates a practical problem: the legal situation can change at short notice without immediate awareness. Anyone dealing with such substances should therefore be aware that supposed legality is not a reliable constant but part of a dynamic regulatory development.

Legal LSD derivatives such as 1BP-LSD and 1Fe-LSD primarily carry psychological risks. Physical effects such as dilated pupils and increased heart rate are usually harmless.

The main acute risk is the "bad trip" (anxiety, paranoia), influenced by "set," "setting," and dose, which can lead to impulsive behavior.

In the long term, there is a possibility of developing rare HPPD (hallucinogen persisting perception disorder) or exacerbating existing mental disorders (such as schizophrenia) in predisposed individuals.

For this reason, individuals with such pre-existing conditions are advised against consumption. The potential for abuse and dependence is low due to rapid tolerance development and the absence of physical withdrawal.

Combining with other substances is dangerous: alcohol causes nausea/disorientation; stimulants increase heart rate/anxiety; cannabis unpredictably intensifies the effects; certain medications (e.g., lithium, MAOIs) can cause life-threatening interactions. Thorough information about interactions is essential.

Additionally, those interested in psychedelics should always keep an eye on the legal situation to be able to react promptly to prohibitions and new developments and avoid penalties.

• Carhart-Harris, R. L., & Nutt, D. J. (2010). User perceptions of the benefits and harms of hallucinogen use: a web-based questionnaire study. Journal of Substance Use, 15(4), 283-300.

• Cohen, S. (1960). Lysergic acid diethylamide: side effects and complications. Journal of Nervous and Mental Disease, 130(1), 30-40.

• De Gregorio D., Aguilar-Valles A., et al. (2021). Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine. J Neurosci. 2021 Feb 3;41(5):891-900. doi: 10.1523/JNEUROSCI.1659-20.2020.

• Evans J., Aixalà M., Anderson B.T., Brennan W., Bremler R., Breeksema J.J., Burback L., Calder A.E. et al. (2025). On Minimizing Risk and Harm in the Use of Psychedelics. Psychiatr Res Clin Pract. 2025 Feb 11;7(1):4-8. doi: 10.1176/appi.prcp.20240128. (Universitätsklinikum Freiburg)

• Halpern, J. H., & Pope, H. G. (1999). Hallucinogen persisting perception disorder: what do we know after 50 years? Drug and alcohol dependence, 56(3), 177-185.

• Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human hallucinogen research: guidelines for safety. Journal of psychopharmacology, 22(6), 603-620.

• Kopra, J., van der Mandele, R., Kuypers, K. P. C., & Winstock, A. R. (2022). Adverse experiences resulting in emergency medical treatment seeking following lysergic acid diethylamide (LSD) use. Journal of Psychopharmacology, 36(11), 1276–1285.

• Nichols, D. E., & Grob, C. S. (2018). Is LSD toxic? Forensic science international, 284, 141-145.

• Schmid, Y., Enzler, F., Gasser, P., Grouzmann, E., Preller, K. H., Vollenweider, F. X.,... & Liechti, M. E. (2015). Acute effects of lysergic acid diethylamide in healthy subjects. Biological psychiatry, 78(8), 544-553.

• Strassman, R. J. (1984). Adverse reactions to psychedelic drugs. A review of the literature. The Journal of nervous and mental disease, 172(10), 577-595.